|
SLC25A17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
8.31879998219875E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
5.953000E-01 |
| Stage1-vs-Stage3 |
1.176000E-01 |
| Stage1-vs-Stage4 |
6.44659999999853E-05 |
| Stage2-vs-Stage3 |
1.430780E-01 |
| Stage2-vs-Stage4 |
3.281000E-03 |
| Stage3-vs-Stage4 |
2.408100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.73709999998317E-06 |
| Normal-vs-Asian |
1.64146474190829E-12 |
| Caucasian-vs-AfricanAmerican |
8.267600E-01 |
| Caucasian-vs-Asian |
7.979600E-01 |
| AfricanAmerican-vs-Asian |
9.426200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.042000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62569957495862E-12 |
| Normal-vs-Age(81-100Yrs) |
1.830440E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.707800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.082600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.089800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.482800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.204600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.813000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.288200E-02 |
| Classical-VS-Follicular |
7.349200E-01 |
| Classical-VS-Other |
3.209200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
5.991700E-02 |
| Tall-VS-Other |
8.817000E-01 |
| Tall-VS-Normal |
2.22044604925031E-16 |
| Follicular-VS-Other |
3.820800E-01 |
| Follicular-VS-Normal |
1.8677281943269E-12 |
| Other-VS-Normal |
3.73559999999884E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
9.617900E-03 |
|
|
